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2.9.3 Elastase-ai-Proteinase Inhibitor Complex 
Human granulocyte elastase ( E C 3.4.21.37) complexed with arproteinase 
inhibitor from plasma 
Siegfried Neumann and Marianne Jochum 
General 
Human neutrophil leukocytes are rich in lysosomal neutral proteinases which are 
primarily responsible for intracellular protein breakdown in phagosomes. The best 
known enzyme of this group, an elastase, is one of the major constituents of the 
azurophilic granules of the polymorphonuclear leukocytes. As shown originally by 
Janoff ά Scherer [1], granulocyte elastase can degrade elastin in vitro as well as 
various connective tissue proteins and plasma factors. Hence, the enzyme may play an 
important pathogenic role in tissue destruction and consumption of plasma factors, 
especially of clotting factors, i f it is liberated extracellularly from the phagocytes 
during inflammatory diseases (for reviews, cf. [2]). Present evidence suggests that the 
amount of granulocyte elastase released extracellularly reflects the response of the 
organism to an inflammatory stimulus thus indicating the degree of participation of 
lysosomal factors in the inflammatory process. 
In plasma samples, granulocyte elastase is found exclusively in complexes with 
plasma proteinase inhibitors [3, 4], primarily with the a rproteinase inhibitor (former­
ly called a rantitrypsin). Although approximately 10% of the elastase liberated may 
be bound to a2-macroglobulin [3], the elastase-a2-macroglobulin complex is normally 
hardly detectable in plasma samples due to the distinctly more rapid elimination of 
this complex (tx/1 ~ 10 min) from the circulation compared to the elastase-arpro-
teinase inhibitor complex (t{/2 - 1 h). Whereas the a2-macroglobulin-bound elastase 
is still able to hydrolyze peptide substrates, the enzyme is totally inactive in the 
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complex with the α proteinase inhibitor. However, elastase in this inactive complex is 
still accessible to specific antibodies. 
Application of method: in clinical pathology, clinical chemistry, experimental cell 
research, haematology etc. 
International reference methods and standards: not yet available. 
Enzyme properties relevant in analysis: granulocyte elastase (EC 3.4.21.37) is a catio-
nic glycoprotein with a molecular weight close to 30000 [4,5]. Most of the enzyme 
preparations obtained so far can be separated into three multiple forms by ion-ex­
change chromatography [4, 5]. 
The three elastase forms give a reaction of identity in immunodiffusion and crossed 
Immunoelectrophoresis [5]; they are also very similar with respect to their enzymatic 
or catalytic properties, at least towards synthetic peptide substrates. Elastase from 
human pancreas is a quite different protein which does not cross-react with antiserum 
against granulocyte elastase [6]. The same holds true for blood platelet elastase [7]. 
Granulocyte elastase reacts with its major natural antagonist in the human organ­
ism, the a rproteinase inhibitor, by forming a stable equimolar complex with a molec­
ular mass of approximately 80000 [3, 4]. A minute transfer of the enzyme from this 
complex to free a2-macroglobulin was reported by one group [3,8]. The significance 
of this observation is not yet clear. 
Methods of determination: elastase has been demonstrated immunologically in plasma 
samples of patients with septicaemia or leukaemia [9], in sera of myeloid leukaemia 
patients [10], in peritoneal fluid of peritonitis patients [11] and in sputum from bron­
chitis patients [12]. Immunochemical techniques described so far for elastase estima­
tion are electro-immunodiffusion [9,11], radioimmunoassay [6,13], and a competi­
tive type of solid-phase enzyme-linked immunoassay [14]. 
A sandwich type of solid-phase enzyme-linked immunoassay, which includes anti-
sera against both elastase and α proteinase inhibitor, was described recently [15a,b]*. 
Results on elastase/α proteinase inhibitor levels in septicaemia or leukaemia [16] and 
rheumatoid arthritis [17] were reported previously. A version of this assay carried out 
in tubes is given below in detail. 
Enzyme effectors: reversible inhibitors of active elastase include some long-chain fatty 
acids and polysaccharide sulphates, as well as the microbial peptide derivatives elasta-
tinal and elasnin (for a review, cf. [18]). Irreversible inhibitors include the typical serine 
proteinase inhibitors diisopropyl fluorophosphate and phenylmethane sulphonyl-
fluoride, and also methoxysuccinyl-Ala-Ala-Pro-Val-CH2C1 which is a rather specific 
inhibitor of granulocyte elastase [18]. The soybean trypsin inhibitor (Kunitz) and 
inhibitory proteins from human seminal plasma and bronchial mucus, antileukopro-
teinase(s), are also known effectively to inhibit granulocyte elastase [19]. 
* Note added in proof: while this manuscript was in preparation an assay which is based on the same 
principle was published by a different group [24]. 




(a) spAb E + E I spAb E -EI + EI 
(B,) (F t) 
(b) spAb E -EI + Abf spAb E -EI-Abf + Abf 
(B 2) (F 2) 
B 2 
(c) 4-Nitrophenyl-P + H 2 0 • 4-nitrophenolate + P j . 
Sheep antibodies against elastase from human granulocytes are fixed to polystyrene 
tubes by adsorption. In reaction (a) the elastase inhibitor complex in either a standard 
solution or an unknown sample is reacted with the solid phase antibody. Free complex 
is then removed by washing the tubes. In reaction (b) the bound complex fraction 
from the first step (Bj) is reacted with the labelled antibody to a rproteinase inhibitor. 
Free labelled antibody is removed subsequently, and the bound label (B 2 ) is detected 
by incubation of the tubes with a chromogenic substrate in reaction (c). Substrate 
hydrolysis is stopped after a fixed time and absorption at 405 nm is measured. Assay 
blanks are made with sample diluent as a specimen. 
Optimized conditions for measurement: calibrators and unknown samples are run in 
parallel and sample data are calculated from the calibration curve. Therefore, stand­
ardization with regard to temperature is optional within the range of 20 °C to 25 °C as 
long as all tubes within the series are treated in the same way. Since the immune 
reaction may not reach equilibrium within the incubation periods, the times of 
addition and removal of immunological reactants to and from the tubes have to be 
strictly controlled. 
Equipment 
Spectrophotometer or spectral-line photometer with precise measurement of absorb-
ance at 405 nm, preferably with a flow cuvette for 0.5 or 1.0 ml; precision pipettes for 
0.05, 1.0 and 2.0 ml; suction device (i.e. water pump etc.) with a trap; stopwatch. 
spAb E solid phase fixed antibodies to granulocyte elastase. 
E I complex of granulocyte elastase with α j-proteinase inhibitor. 
Ab* antibodies to ocrproteinase inhibitor with alkaline phosphatase as a label. 
B t , B 2 bound fractions from first or second reaction. 
F j , F 2 free fractions from first or second reaction. 
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Reagents and Solutions 
Purity of reagents: all chemicals should be of the highest analytical grade com­
mercially available. The antibodies against human granulocyte elastase should give 
only one precipitin line with extracts from leukocyte granules, i.e. they should react 
only with elastase and should not react with human plasma proteins. Suitable specific 
antisera against α proteinase inhibitor can be obtained from different commercial 
suppliers. Purified immunoglobulin fractions of the rabbit antiserum are commer­
cially available from Dako. The alkaline phosphatase used as a label is of the highest 
purity grade; suitable commercial preparations are available. 
Preparation of reagents (for 96 determinations): all solutions in re-purified water (cf. 
Vol . I I , chapter 2.1.3.2). 
1. Antibody-coated tubes: 
prepare coating solution by dissolving 5 mg immunoglobulin fraction of sheep 
antiserum (e.g. from Seward Lab.s London, U.K.) against human granulocyte ela­
stase in 100 ml NaCl, 0.15 mol / l (i.e. saline; dissolve 8.77 g NaCl in 100 ml water). 
Fill 96 polystyrene tubes (10.5 mm diameter and 40 mm height) with 1 ml coating 
solution and incubate at 2 ° C to 8 °C for 24 h. Decant solution afterwards and rinse 
tubes three times with 2 ml saline. Aspirate the rest of the fluid carefully with the 
help of a water pump. Tubes are then ready for use. For prolonged storage the 
coated tubes may be washed finally with water, dried in vacuo and stored in air­
tight containers with a desiccant until use. Wash these tubes with saline once and 
aspirate all fluid before use. 
2. Conjugate buffer (Tris, 0.01 mol / l , pH 7.5; NaCl, 0.15 mol / l ; MgCl 2 , 2 mmol/1; 
ZnCl 2 , 0.025 mmol/1; dodecyl hydrogen sulphate, 1 mmol/1; bovine serum albu­
min, lOg/ i ) : 
dissolve 0.121 g Tris and 0.877 g NaCl in 50 mi water, adjust to pH 7.5 with HCl , 
2 mol / l ; then add 1 ml MgCl 2 , 0.2 mol/ l (4.066 g MgCl 2 · 6 H 2 0 in 100 ml water) 
and 0.1 ml ZnCl 2 , 25 mmol/1 (0.341 g ZnCl 2 in 100 ml water); dissolve 29 mg 
dodecyl hydrogen sulphate, sodium salt, and 1 g bovine serum albumin and finally 
dilute to 100 ml with water. 
3. Antibody-enzyme conjugate (1 mg/ml): 
antibodies against α proteinase inhibitor are purified from rabbit antiserum by 
fractionation by ammonium sulphate precipitation and ion-exchange chromato­
graphy by an established procedure [20]. Alternatively, the immunoglobulin frac­
tion of rabbit antiserum available from a commercial source (e.g. from Dako etc.) 
may be used. The antibodies are conjugated with calf intestinal alkaline phospha­
tase as described in the Appendix, p. 192. A final conjugate solution with an anti­
body titre of 1 mg antibody against α proteinase inhibitor per litre and an alkaline 
phosphatase activity of approximately 700 U / l is used. 
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4. Sample diluent (phosphate, 0.01 mol/1, pH 7.5; NaCl 0.15 mol/1; EDTA, 
20 mmol/1; bovine serum albumin, 1 g/1): 
dissolve 42.8 mg K H 2 P 0 4 , 0.3 g N a 2 H P 0 4 · 2 H 2 0 , 1.75 g NaCl and 1.49 g EDTA 
in 50 ml water, adjust to pH 7.5 with NaOH, 1 mol/1, dissolve 0.2 g bovine serum 
albumin and dilute to 200 ml with water. 
5. Standard solutions 
Stock solution 
Enzyme solution: dissolve 0.5 mg purified granulocyte elastase in 1 ml NaCl, 0.15 
mol/1. 
Inhibitor solution: dissolve 2.8 mg a rproteinase inhibitor in 1 ml Tris /HCl, 60 
mmol/1, pH 8.0, containing NaCl, 0.15 mol/1 (0.725 g Tris and 0.877 g NaCl in 50 
ml water, adjust to pH 7.5 with HCl , 2 mol/1, and dilute to 100 ml with water). 
Mix equal volumes of enzyme and inhibitor solution and incubate for 30 min at 
37 °C. Check by Polyacrylamide gel electrophoresis that the enzyme is totally 
complexed [4]. 
Diluted standard solution: dilute stock solution of complex to a final concentration 
of 10 ng elastase/ml by serial dilution in sample diluent (4). Similarly, prepare 
standard solutions containing 5, 2.5 and 1 ng elastase in complex form per ml. 
6. Washing solution (polyoxyethylene sorbitol monolaurate, 0.05% (w/v)): 
dissolve 0.25 g polyoxyethylene sorbitol monolaurate in 500 ml water. 
7. AP assay reagents 
7a. DEA buffer (1 mol/1, pH 9.8; M g 2 + , 0.5 mmol/1): 
dissolve 9.65 ml diethanolamine in 50 ml water, adjust to pH 9.8 with HCl, 
1 mol/1, add 0.25 ml MgCl 2 , 0.2 mol/1, and dilute to 100 ml with water. 
7b. 4-Nitrophenyl phosphate (10 mmol/1): 
dissolve 371 mg 4-nitrophenyl phosphate, disodium salt, hexahydrate in 100 ml 
buffer (7a). 
8. NaOH (2 mol/1): 
dissolve 8 g sodium hydroxide in 50 ml water, and dilute to 100 ml with water. 
Stability of solutions: prepare 4-nitrophenyl phosphate solution (7b) freshly every day 
and store in the dark. Store standard solutions (5) at - 20°C until use and thaw once 
only. The antibody-coated tubes can be stored for 4 weeks at 2 ° C to 8 °C without 
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decrease of quality when stored wet after rinsing as described under solution (1). 
Dried coated tubes can be stored for 1 year at 2 ° C to 8°C with negligible loss of func­
tion. A l l other reagents are stable for 4 weeks i f kept in the refrigerator ( + 4°C) and as 
long as no microbial contamination occurs. 
Procedure 
Collection and treatment of samples: collect blood from the vein into syringes or 
plastic tubes containing solid sodium citrate (3.8 mg sodium citrate for 1 ml) or EDTA 
(2 mg EDTA for 1 ml) as an anticoagulant. Do not shake blood vigorously during 
transport or storage. Store blood in cool conditions and remove plasma as quickly as 
possible. 
Centrifuge for 10 min at about 3000 g and separate plasma from buffy coat so as 
not to disturb the buffy coat. Whereas heparinized plasma can also be used in this 
assay, serum cannot be used because elastase is liberated from granulocytes during 
clotting, thus causing falsely increased levels of the complex [22]. 
Stability of the analyte in the sample: the antigenic properties of the e l a s t a s e / α p r o ­
teinase inhibitor complex in plasma are preserved for at least 24 h at 2 ° C to 8 °C and 
for more than 6 months during storage at - 20°C. In samples from other sources (e.g. 
synovial fluids, effusions, seminal plasma etc.) the complex was found to be stable at 
- 2 0 ° C . 
Assay conditions 
Incubation 
Dilute plasma or other specimen with sample diluent. It is most convenient to mix 
50 μΐ plasma sample with 2.5 ml sample diluent in a polypropylene tube. 
A l l measurements in duplicate. 
A reagent blank with sample diluent (4) instead of sample is run. 
Standard assays with standard solution (5) instead of sample are run, using 10, 5, 
2.5 and 1 ng elastase in complex form per ml. 
Start pipettings with blank, followed by standard and sample assays. It is essential 
to pipette in this sequence with constant time intervals throughout the incubation 
procedure. 
It is not possible to indicate any concentration of reactants in the incubation 
mixture since reaction occurs on the solid phase. 
Colour reaction 
Wavelength 405 nm; light path 10 mm; final volume for absorbance reading 0.5 or 
1.0 ml . 
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A blank is run with a mixture of 0.5 ml 4-NPP (solution (7b) and 0.5 ml NaOH, 
2 mol/1. 
A calibration curve is constructed with absorbances corrected for blank (ordinate) 
versus complexed elastase concentration (abscissa). A linear correlation should result. 
Measurement 
Pipette into coated tubes: 
sample diluent (4), 
diluted sample 
or standard solution (5) 0.5 ml 
incubate 1 h at room temperature (20 °C to 
25 °C), aspirate the contents 
washing solution (6) 2.0 ml 
mix well, aspirate carefully, repeat washing two 
more times 
antibody-conjugate (3) 0.5 ml 
incubate 1 h at room temperature, aspirate 
contents 
washing solution (6) 2.0 ml 
aspirate contents carefully 
4-NPP solution (7b) 0.5 ml 
incubate 90 min at room temperature in the dark 
NaOH solution (8) 0.5 ml 
mix, transfer contents into cuvettes, read 
absorbance. 
Calculation: calculate mean values of duplicate measurements. A calibration curve is 
constructed on a linear graph paper with absorbances corrected for blank (ordinate) 
versus concentration of complexed elastase (abscissa), given as μg elastase per litre. A 
linear correlation should result. Calculate intercept at 0 μg/l and slope of the curve by 
linear regression. 
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Read concentrations of unknown samples from the calibration curve. The concen­
tration in the undiluted analyte is calculated by multiplying the concentration in the 
diluted sample by the factor by which the analyte was diluted before the assay (e.g. 
factor 51 for plasma diluted by mixing 50 μΐ plasma with 2.5 ml sample diluent as 
described under "Assay conditions"). 
Validation of Method 
Precision, accuracy, working range, detection limit and sensitivity: for two plasma 
pools with concentrations of about 50 μg/l and 200 μg/l granulocyte elastase com-
plexed with α proteinase inhibitor, the standard deviations were ± 4 and ± 8 μg/ l . 
Within a series of 15 determinations the relative standard deviations (referred to the 
means values) were 7.7 and 3.9%, respectively. A coefficient of variation of approxi­
mately 8% was found for the between-series imprecision with 15 series. Data on 
accuracy are not available since standard reference material is not established yet. 
Standards mixed with plasma gave a recovery close to 100%. 
The working range of the assay described is between 0.5 and 5 ng of elastase per 
assay tube, i.e. 1 to 10 ng/ml. When plasma diluted 1: 51 is used this equals a range of 
51 to 510 μg elastase per 1 undiluted plasma. The detection limit is defined as the mean 
absorbance of the reagent blank plus three times its standard deviation. It is about 
0.25 ng elastase per test tube, i.e. 0.5 ng/ml. It can be lowered by increasing the 
incubation times for the immune reactions (a) and/or (b). The sensitivity corresponds 
to a ΔΆ = 0.005 in the calibration curve and approaches 0.2 ng elastase/ml. 
Sources of error: interference by improper handling of blood has been described [22, 
23]. Addition of haemoglobin, lipids or rheumatic factors to plasma does not affect 
the assay [23]. Free α proteinase inhibitor, which is present in high excess over the 
complex in plasma, does not interfere i f sufficient washing is done following immune 
reaction (a) in the assay described above. Influences by therapeutics on the measured 
elastase concentrations are unknown so far [23]. 
Specificity: the concentration of the granulocyte elastase/α proteinase inhibitor com­
plex is measured specifically by making use of two distinct immunochemical reagents, 
specific antibodies directed towards granulocyte elastase and towards α proteinase 
inhibitor. Elastase from pancreas or platelets and neutral proteinases other than gra­
nulocyte lysosomal elastase do not interfere in the assay. 
Reference ranges: in human citrated plasma: 30 to 160 μg elastase/1 [15b]. In another 
report a range between 10 and 160 μg elastase/1 was found, with a median of 61 μg/l 
[23]. No difference was seen between sexes. Note that the given values represent the 
amount of elastase present in the complex and not the elastase-a proteinase inhibitor 
complex in total. 
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Appendix 
Preparation of antibody-enzyme conjugate 
Reagents 
Immunoglobulin 
Purify the immunoglobulin fraction from rabbit antiserum against human (^-pro-
teinase inhibitor by ammonium sulphate fractionation and ion-exchange chromato-
graphy of antiserum according to a published procedure [20], or obtain as a commer-
cial preparation (e.g. from Dako etc.). 
Alkaline phosphatase 
Use AP from calf intestine from commercial suppliers (e.g. Boehringer Mannheim, 
Sigma etc.) supplied as reagent grade, "for use as a marker in enzyme-linked immuno-
assays", in buffered solution. 
Bovine serum albumin 
Obtain the highest grade of purity commercially available. 
Solutions 
1. Phosphate-buffered saline (15 mmol/1, pH 7.5; NaCl, 0.135 mol/1): 
dissolve 320 mg K H 2 P 0 4 , 2.25 g N a 2 H P 0 4 - 2 H 2 0 and 7.89 g NaCl in 500 ml 
water, adjust to pH 7.5 with NaOH, 1 mol/1, and dilute to 1000 ml with water. 
2. Glutardialdehyde reagent (2 .1% (v/v); phosphate, 15 mmol/1, pH 7.5; NaCl, 0.135 
mol/1): 
mix 0.1 ml 25% (v/v) glutardialdehyde (as obtained from commercial suppliers in 
sealed ampoules, highest grade of purity available) with 1.1 ml phosphate-buffered 
saline (1). Prepare this solution freshly before use. 
3. Tris-buffered saline/Mg/Zn (Tris, 10 mmol/1, pH 7.5; NaCl, 0.15 mol/1; MgCl 2 , 
2mmol/1; ZnCl 2 , 0.025 mmol/1): 
dissolve 0.121 g Tris and 0.877 g NaCl in 50 ml water, adjust to pH 7.5 with HCl , 
2mol/1, then add 1 ml MgCl 2 , 0.2 mol/1 (dissolve 4.066 g MgCl 2 - 6 H 2 0 in 100 ml 
water), add 0.1 ml ZnCl 2 , 25 mmol/1 (dissolve 0.341 g ZnCl 2 in 100 ml water), and 
dilute to 100 ml with water. 
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4. Conjugate buffer (Tris, 10 mmol/1, pH 7.5; NaCl, 0.15 mol / l ; MgCl 2 , 2 mmol/1; 
ZnCl 2 , 0.025 mmol/1, dodecyl hydrogen sulphate, 1 mmol/1; bovine serum albu­
min, 10 g/l): 
dissolve 29 mg dodecyl hydrogen sulphate, sodium salt, and 1 g bovine serum albu­
min in 100 ml Tris-buffered saline/Mg/Zn solution (3). 
Protein coupling 
The antibody and alkaline phosphatase protein preparations are coupled by glutar-
dialdehyde in an one-step procedure described previously [21]. 
Prepare the immunoglobulin in solution either by dissolving 10 mg (dry weight) 
purified immunoglobulin fraction in 1 ml phosphate-buffered saline (1), or by diluting 
immunoglobulin solution obtained commercially to a final concentration of 10 mg 
protein/ml using solution (1) as a diluent. Dialyze the solution against solution (1) at 
2 ° C to 8 °C for 48 h with one change of the dialysis buffer. 
Dialyze the alkaline phosphatase solution against solution (1) as described for the 
antibody solution and finally adjust the enzyme to 1.2 mg protein/ml by dilution. 
Mix 1 ml immunoglobulin solution with 4.2 ml dialyzed enzyme solution and add 
0.26 ml glutardialdehyde reagent (2). Mix thoroughly and incubate without further 
shaking for 2 h at room temperature. Dialyze mixture against solution (1) overnight at 
2 ° C to 8 ° C , then change dialysis buffer to Tris-saline/Mn/Zn solution (3) and dialyze 
for 48 h in the refrigerator. 
Chromatography of the conjugate 
Add the dialyzed coupling mixture to the top of a column (25 mm diameter χ 1000 mm 
height) packed with an appropriate separation medium (e.g. Bio-Gel® A 1,5 m from 
Bio-Rad Labs., Munich; Sephadex® G 200 (from Pharmacia) previously equilibrated 
with Tris/saline/Mg/Zn solution (3). Elute the sample with a flow rate of 4 ml x h - 1 
χ c m - 2 and collect fractions of 5 ml. Assay for activity of alkaline phosphatase in the 
eluate. The enzyme-labelled antibodies elute in the first enzyme peak which appears in 
the void volume. Peak fractions are pooled. Add dodecyl hydrogen sulphate, sodium 
salt, and bovine serum albumin to the pool to give final concentrations of 290 mg and 
10 g, respectively, per 1 1 of pool volume. 
Characterization of the conjugate 
Determine the antibody titre of the conjugate pool from the column and dilute with 
conjugate buffer (4) to a final concentration of approximately 1 mg of specific anti­
body against α proteinase inhibitor per litre. Check by enzyme-immunoassay that 
this solution will give a suitable absorbance reading with the highest calibrator in the 
assay; in case of unacceptably high readings, dilute conjugate with a solution contain­
ing 1 mg of unlabelled antibody against α proteinase inhibitor per litre. 
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Storage 
Store conjugate in solution at 2 ° C to 8 ° C . To prevent microbial growth add appro­
priate preservatives, for instance sodium azide, 0.2 g/1, and organomercurials, 0.2 g/1. 
Under these conditions the conjugate is stable for at least 12 months. 
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